Panadeine (Acetaminophen,Codeine)

Quick links to important sections

Panadeine (Acetaminophen,Codeine)

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Panadeine (Acetaminophen,Codeine)

Quick Facts

Property Description
Active Ingredients Acetaminophen, Codeine
Form Fixed-dose combination (FDC) oral tablet
Pharmacological Class Combination Analgesic (Non-opioid and Opioid derivative)
Common Use Alleviation of moderate pain
Origin Synthetic (Acetaminophen) and naturally derived (Codeine)

What Type of Medicine is Panadeine (Acetaminophen, Codeine)?

Panadeine is pharmacologically defined as a combination analgesic, specifically a fixed-dose combination (FDC) oral preparation, intended for the comprehensive management of pain. The FDC format ensures the simultaneous delivery of two active ingredients, which is clinically recognized for providing enhanced efficacy in relieving moderate pain that exceeds the threshold manageable by single-agent non-opioids. The product's overall therapeutic goal is the alleviation of moderate pain.

Composition and Classification: Acetaminophen and Codeine

The drug’s identity is founded upon its two active ingredients: the synthetic Acetaminophen (INN Paracetamol) and the naturally derived Codeine, which is classified as an opioid alkaloid derivative. Codeine is a prodrug—a substance that requires metabolic conversion by the body into Morphine to exert its primary analgesic effect. This specific composition differentiates it from non-opioid formulas and other combination analgesics, positioning it for targeted pain intervention. The combination is also widely known by common generic names like Co-Codamol.

General Purpose of the Combination Analgesic

The general purpose of this specific FDC is to provide synergistic pain management by engaging different pathways in the nervous system. The combination is intended to deliver greater efficacy by leveraging Acetaminophen's action on central pain-signaling messengers with Codeine's central modulation of pain perception. This mechanism rationale underpins its utility in providing comprehensive pain control, often used in scenarios like post-procedure discomfort, for patients whose needs exceed the efficacy profile of single-agent non-opioids.

What side effects are possible with Panadeine (Acetaminophen,Codeine)?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety constraints for acetaminophen and codeine as documented in official government regulatory sources.

Adverse Reaction Scope

The safety profile is primarily defined by high-level effects on the Central Nervous System and the potential for Hepatic System damage. Reactions are categorized by frequency and the physiological system affected:

Classification Examples of Officially Documented Effects
Common (Gastrointestinal / CNS) Drowsiness, Nausea, Vomiting, Constipation, Dizziness, Headache, Sedation.
Rare / Very Rare (Dermatological) Serious skin reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Serious Adverse Reactions

The most serious reactions explicitly documented in regulatory labeling include Life-Threatening Respiratory Depression, which is noted as being most likely at treatment initiation or following a dose increase. Additionally, the risk of Severe Hepatotoxicity (liver damage), which may be fatal, is tied to the acetaminophen component. Other serious risks include Neonatal Opioid Withdrawal Syndrome and potential Anaphylaxis.

Population-Specific Safety Constraints

Official documents impose specific safety constraints on certain populations. The medicine is contraindicated for pain relief in children under 12 years of age and in adolescents under 18 years following tonsillectomy or adenoidectomy. Use during lactation is not recommended. Individuals identified as Ultra-Rapid Metabolizers of codeine are at a higher documented risk of opioid toxicity.

Exposure-Related Safety Patterns

Regulatory labels indicate that prolonged or chronic use carries the risk of Physical and Psychological Dependence, which is a defining safety constraint of the medicine. The official labeling also highlights the inherent risk of Addiction, Abuse, and Misuse.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented manifestations and required emergency actions for Panadeine (Acetaminophen, Codeine) overdose, strictly as stated in government regulatory documents.


Overdose Scope

Domain Official Regulatory Statements
Documented overdose presentations Overdose involves distinct risks: Opioid Toxicity (Codeine), shown by depression of respiration, pinpoint pupils, and somnolence progressing to coma; and Hepatotoxicity (Acetaminophen), presenting initially with nausea, vomiting, and diaphoresis.
Physiological systems affected Central Nervous System, Respiratory System, Hepatic System, and Cardiovascular System.
Dose-related or exposure-related factors High exposure to the Acetaminophen component carries the documented risk of dose-dependent, potentially fatal hepatic necrosis.
Population-specific overdose notes Ultra-rapid metabolisers (CYP2D6) are at increased risk for opioid toxicity. Pre-existing hepatic impairment increases the risk of liver injury from Acetaminophen.
Emergency-response statements Naloxone is the specified antagonist for opioid toxicity, and N-acetylcysteine is the documented antidote for Acetaminophen toxicity. Supportive measures include support of cardio-respiratory function and assisted ventilation.
When immediate medical help is required Regulatory labeling mandates that individuals seek immediate medical attention or contact emergency services immediately upon suspicion of overdose, as severe liver injury may be delayed. Hospital monitoring/admission may be required.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification Overdose may lead to life-threatening circulatory and respiratory depression, fatal hepatic necrosis, and death.
Overdose-context constraints Management requires observation for a minimum of four hours due to the potential for delayed toxicity.

Resulting Overdose Structure

Official overdose statements:

  • Overdose presents with dual risks: immediate respiratory depression and delayed acute liver failure, both classified as life-threatening events.
  • Official management includes using Naloxone for Codeine toxicity and N-acetylcysteine for Acetaminophen toxicity, alongside symptomatic and supportive treatment.
  • Regulatory documents mandate that medical attention be sought immediately for any suspected overdose because the severe liver damage can be fatal and its clinical manifestations may be delayed.

Connection to the overall overdose profile (3 sentences): The regulatory profile is defined by the dual risks of immediate respiratory depression and delayed acute liver failure, both of which dictate that the official emergency procedures require that patients seek immediate medical attention. This action is necessary for continuous monitoring of vital signs and the administration of the component-specific antidotes documented in the prescribing information. The guidance is structured to address both the rapid-onset central nervous system effects and the progressive, dose-dependent hepatic damage.

Therapeutic Uses of Panadeine (Acetaminophen,Codeine)

What Panadeine (Acetaminophen, Codeine) Treats: Main Uses and Benefits

The combination of acetaminophen and codeine is commonly used to help relieve mild to moderate pain and to address fever, generally in situations where additional symptomatic support is needed.

Enhanced Relief for Acute Symptom Manifestations

This medication is applied in therapeutic contexts involving symptoms related to heightened physiological activity and discomfort. It is considered relevant for easing symptoms related to discomfort, such as headaches, musculoskeletal strain, neuralgia, or pain associated with dental procedures. It may contribute to improved day-to-day comfort during periods of heightened symptoms.

“This medication may provide short-term assistance in managing pronounced symptoms of discomfort.”

Symptom Management in Recovery and Episodic Conditions

Panadeine is commonly used across conditions presenting with acute or episodic symptom patterns, often in scenarios following minor procedures or when managing short-term pain from injuries like sprains. It offers symptomatic relief that helps patients cope more steadily with these episodes and may assist with maintaining functional stability. Used across clinical settings that involve acute or unstable symptom patterns, this combination generally helps moderate the overall symptom intensity.

Quick Fact: Relief for Pain and Fever – Panadeine is applied when symptoms create noticeable functional strain or discomfort and requires temporary, supportive relief.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Panadeine (Acetaminophen,Codeine)?

Eligibility Scope

Classification Population Status
Standard Use Adults (generally ge 18 years) Allowed
Restricted Use Adolescents (12–18 years) Caution Required
Contraindicated Children younger than 12 years Must Not Use
Contraindicated Breastfeeding Mothers Must Not Use

Official Contraindicated Populations

Official regulatory documents classify several populations who must not use this medicine under any circumstances. The combination is contraindicated in all children younger than 12 years of age for all uses. Use is also strictly prohibited in all patients younger than 18 years following tonsillectomy and/or adenoidectomy, regardless of the reason for surgery, due to the risk of life-threatening respiratory depression. Furthermore, the medicine is contraindicated for breastfeeding mothers and for individuals known to be CYP2D6 ultra-rapid metabolizers.

Conditional Use Requirements

Other populations require special caution or restriction. Use is not recommended in adolescents aged 12 to 18 years who have risk factors for respiratory problems, such as severe lung disease or obstructive sleep apnea. Older adults and patients with severe renal impairment or hepatic insufficiency require caution, often necessitating lower initial doses or limits on total daily acetaminophen intake. The medicine is also contraindicated in patients with acute respiratory depression or known hypersensitivity to any component.

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

The regulatory profile for Panadeine (Acetaminophen, Codeine) includes several documented pharmacokinetic and pharmacodynamic constraints for co-administration with other medicines and substances.

Contraindicated Combinations and Genetic Constraint

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited in regulatory documents due to the risk of severe Serotonin Toxicity. Furthermore, the product is officially contraindicated for CYP2D6 Ultra-rapid Metabolizers, as this genetic metabolic interaction can result in excessive levels of the active metabolite, increasing the risk of life-threatening respiratory depression.

Pharmacokinetic and Exposure Interactions

  • CYP2D6 Inhibitors (e.g., Amiodarone, Quinidine, Paroxetine) are documented to decrease the plasma concentration of the active metabolite, which may result in reduced analgesic efficacy.
  • CYP3A4 Inhibitors increase Codeine plasma concentration, potentially causing prolonged adverse reactions. Conversely, CYP3A4 inducers may lead to decreased efficacy.
  • The Acetaminophen component may increase the anticoagulant effect of Coumarin Derivatives (e.g., Warfarin), increasing the risk of bleeding.

Pharmacodynamic and Substance Restrictions

  • The combination causes additive CNS depression when co-administered with Central Nervous System (CNS) Depressants, including alcohol (ethanol), which is formally restricted in use. This additive effect is documented to increase the risk of profound sedation.
  • Interactions with Serotonergic Drugs are noted to increase the risk of Serotonin Syndrome.
  • Interaction effects may be increased in patients with severe hepatic or renal impairment due to reduced drug clearance.

Mechanism of Action

How Panadeine (Acetaminophen/Codeine) Works

The mechanism of action for this combination compound involves the distinct, yet complementary, biochemical actions of its two components: acetaminophen and codeine. This dual-pathway approach results in a modulation of pain transmission and altered central nervous system (CNS) signaling.


Central mu-Opioid Receptor Engagement

Codeine, following conversion to its active metabolite, acts as an agonist at mu-opioid receptors (mu-OR) within the CNS. These receptors are G-protein coupled receptors (GPCRs). Activation of the mu-OR inhibits ascending nociceptive transmission by hyperpolarizing the postsynaptic membrane and reducing the release of excitatory neurotransmitters from the presynaptic neuron. This engagement reduces the propagation of nociceptive impulses and contributes to the dampening of central sensitization processes.


Non-Opioid Mediated Pathway Adjustment

Acetaminophen's primary action occurs predominantly within the CNS, where it is thought to reduce the synthesis of inflammatory mediators. This mechanism involves the inhibition of cyclooxygenase (COX) enzymes, particularly COX-2 and a potential COX-3 variant, as well as possible modulation of the endocannabinoid system. By reducing the synthesis of prostaglandins crucial for pyretic (fever) and pain signaling, this component contributes to the adjustment of central thermoregulatory mechanisms and pathway signaling.

Dosage and Administration Information

Official Administration Guidelines

The fixed-dose combination of acetaminophen and codeine is authorized solely for oral administration and is available in forms such as tablets, caplets, and oral solutions. The official usage protocol is structured around strict limits and short duration.

Dosing and Scheduling

Standard adult administration involves taking one to two unit doses per intake, with the dose requiring titration to the lowest effective amount necessary. This administration is intermittent, with doses scheduled every four to six hours as needed. It is a mandatory procedural constraint that the total 24-hour intake of codeine does not exceed 360 mg. Critically, the total acetaminophen intake from all sources must not exceed 4000 mg (4 g) in a 24-hour period.

Preparation and Duration

Tablets are generally swallowed whole with water. However, soluble or dispersible forms require specific preparation and must be fully dissolved in a minimum of half a glass of water before ingestion. The overall use pattern is restricted to a short-term course, often specified in official documents as a maximum of three consecutive days for acute symptoms. A missed dose should be skipped if the time to the next dose is short, avoiding the intake of a double dose.

Population Constraints

Official documents impose clear population constraints. The combination is strictly contraindicated in children younger than 12 years of age. Furthermore, it is restricted for use in adolescents under 18 who have undergone tonsillectomy and/or adenoidectomy. Use requires caution and may necessitate a lower dose in patients with severe hepatic or renal impairment.

Recent Clinical Evidence

Research evidence / Overview of Studies for Panadeine (Acetaminophen, Codeine)

This overview summarizes the official clinical research and systematic reviews used to evaluate the combination of acetaminophen and codeine, focusing on the design and scope of the evidence rather than individual advice. The findings describe group patterns observed in studies, which provide context but not individual predictions.


Evidence for Short-Term Acute Pain Management

The core evidence summarized for this combination is based on single-dose, double-blind Randomized Controlled Trials (RCTs) that are often combined in large meta-analyses and systematic reviews used by regulatory bodies. This research was applied in studies examining patient-reported experiences in the context of moderate acute pain, particularly following procedures such as dental or general surgery.

Researchers examined outcomes related to physical discomfort. Studies monitored how symptom intensity or variability evolved in the observed adult populations. Studies reported measurements where a greater number of participants reported achieving a specified change in pain intensity compared to those who received a placebo. Research provides insight into short-term changes, typically focusing on the first few hours after the medication was taken.


Research on Comparative Outcomes

Research examined the outcomes of the combination compared against a placebo and against other analgesic agents, such as non-steroidal anti-inflammatory drugs (NSAIDs). Studies report how symptoms evolved in the observed populations during the study period compared to placebo, contributing to the broader evidence landscape.

However, when studies explored outcomes related to physical discomfort against NSAIDs, findings were mixed. Comparative evidence is not universally consistent, and evidence quality varies across studies, and the data show patterns related to varying degrees of observed change across different trials.


Evidence in Specific Patient Populations

  • Research has explored how response to the drug may be affected by genetic variability. Studies suggest that natural differences in the enzyme responsible for codeine conversion may influence the level of observed change reported by study participants.
  • There is limited information for certain populations, including children and older adults. Authoritative regulatory and scientific reviews have noted that research focusing on the use of codeine-containing combinations in children is particularly scarce and remains an area of uncertainty.

Key Studies & References Acetaminophen and Codeine: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Panadeine (Acetaminophen,Codeine) (FAQ)


Q: What is the main difference between Panadeine and paracetamol-only medicines?

Panadeine is a fixed-dose combination analgesic, meaning it contains two active ingredients: acetaminophen (paracetamol) and codeine. According to official product descriptions, this dual-component approach engages different pathways in the central nervous system to relieve pain. It is intended for the management of pain that may not be adequately addressed by single-ingredient non-opioid medicines alone.

Q: How quickly does Panadeine start working?

Based on the general pharmacological properties described in regulatory documents, the onset of action for the codeine component typically begins within 15 to 30 minutes after taking the medicine orally. Individual response may vary, but this time frame reflects the approximate time of initial absorption and conversion of the drug by the body.

Q: Is Panadeine used for headaches or migraines?

The medicine is primarily indicated for the alleviation of moderate acute pain. Official descriptions in some regulatory documents indicates that this range of uses may include the management of pain associated with headaches and migraines.

Q: Can Panadeine be used to help with a cold or flu?

The combination is not specifically indicated for a cold or flu, but it is approved to alleviate certain common symptoms. The acetaminophen component is known to help reduce fever and pain. Official guidance indicates the total amount of acetaminophen taken from all sources requires careful monitoring.

Q: Are there any known food interactions with Panadeine?

Regulatory guidance for this combination product indicates that it can be taken with or without food. However, as is standard for many oral medications, it is typically taken with water.

Q: Why are people with certain breathing problems advised not to use codeine products?

Official regulatory labels warn about the risk of respiratory depression, which means seriously slowed or shallow breathing. This risk is due to codeine being converted in the body to morphine. This conversion may be excessive in certain individuals or those with underlying breathing issues, potentially leading to severe effects.

Q: What is the relationship between Panadeine and driving ability?

Common side effects of the medication include drowsiness and dizziness, which can impair cognitive function and concentration. For this reason, official drug information includes a warning about operating heavy machinery or driving until the individual understands how the medicine affects them.

Q: Is there a risk of dependence when using Panadeine for a short time?

The documented risk of physical or psychological dependence is generally associated with prolonged or chronic use of the medicine, according to official regulatory labeling. Standard guidelines recommend using the lowest effective amount for the shortest duration necessary for managing acute pain.

Q: Is Panadeine the same as Tylenol with codeine?

Yes, Panadeine is a trade name for the fixed-dose combination of acetaminophen (also known as paracetamol or Tylenol) and codeine phosphate. This combination is also widely known by generic names such as Co-Codamol.

Q: Does taking Panadeine affect blood pressure?

Official product information notes that codeine can cause peripheral vasodilation, which is the widening of blood vessels. This effect may result in episodes of low blood pressure, particularly when rising too quickly, a condition known as orthostatic hypotension.

Q: Are there different strengths of Panadeine available?

Yes, official product records indicate this combination is available in different strengths, which means the amount of codeine component can vary between formulations. For example, 'Panadeine Forte' is an officially recognized higher-strength product compared to standard varieties.

Q: What does official guidance say about using Panadeine during pregnancy?

Official regulatory guidance indicates that the safe use of this combination during pregnancy has not been definitively established. Regulatory documents indicate that the medicine is not generally recommended for use in pregnant women unless a medical evaluation determines that the potential benefits clearly justify any possible hazards to the fetus.

Q: Can I take Panadeine with common over-the-counter allergy medicines?

Combining this medicine with other central nervous system (CNS) depressants is subject to regulatory warnings in official labeling. This class of medications can include some common over-the-counter allergy medicines, such as certain antihistamines. The co-administration of these can lead to additive effects, increasing the risk of profound sedation or slowed breathing.

Q: Does Panadeine lose its effectiveness over time with continuous use?

Official regulatory documentation notes the risk of developing tolerance to the codeine component. Tolerance is a pharmacological effect where the body's response to the substance lessens over time. This may mean that the drug becomes less effective with continuous use.

Q: Does Panadeine interact with herbal supplements?

Yes, official drug information includes warnings about potential interactions with certain herbal supplements. Some supplements may affect the specific enzyme responsible for converting codeine into its active form. This interaction could potentially alter the expected analgesic effect or increase the risk of adverse reactions.

Q: What are the official warnings about using Panadeine after surgery?

Official regulatory documents include specific constraints on the use of this medicine in patients under 18 years of age following a tonsillectomy or adenoidectomy due to specific risks. For other types of surgery, it is noted that the resulting physical stress may worsen certain pre-existing conditions, such as adrenal insufficiency.

Q: What is the difference between Panadeine and Panadeine Forte?

The primary difference is the strength of the codeine component. Panadeine Forte is an officially recognized formulation that contains a higher dose of codeine per unit compared to the standard, lower-strength Panadeine products.

Q: Can Panadeine be crushed or split?

Administration guidelines recommend the tablet form be swallowed whole with water. Official labeling for similar combination tablets often advises against crushing or dissolving them before consumption.

Q: Is Panadeine available over the counter or does it require a prescription?

The availability of this medicine is subject to regulatory control and varies across different countries. In many major jurisdictions, this specific fixed-dose combination of acetaminophen and codeine is generally subject to prescription requirements.

Q: Why do some athletes need to declare Panadeine use?

Codeine is classified as a narcotic analgesic and may be monitored or regulated in competitive sports by anti-doping organizations. Official guidance for athletes may require a Therapeutic Use Exemption (TUE) under specific athletic regulations.

Q: Can Panadeine make me feel anxious or restless?

Official patient information notes that some individuals may experience adverse reactions such as nervousness or sleeplessness. These symptoms are listed in the regulatory documents as effects that may require medical review if they persist.

Q: Can Panadeine affect sleep patterns?

Yes, the medicine can affect sleep due to common side effects like drowsiness and sedation listed in official drug profiles. Furthermore, if the medicine is used for a prolonged duration, withdrawal symptoms upon stopping use may include insomnia.

Q: Is it necessary to take Panadeine with food?

Authoritative regulatory guidance states that it is not necessary to consume the medicine with food. It may be taken with or without a meal, typically swallowed with water.

Q: Are there specific symptoms that require immediate medical attention after taking Panadeine?

Yes, regulatory documents detail several serious adverse reactions that require immediate attention. These documented signs include any changes to breathing (such as it becoming slow or shallow), severe confusion, or signs of liver damage, like the yellowing of the skin or eyes.

How should Panadeine (Acetaminophen,Codeine) be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory labeling defines strict conditions for storing and disposing of acetaminophen and codeine phosphate tablets to ensure product stability and safety.

Storage Conditions

Requirement Details
Temperature Store at or below 25 C (77 F) in a cool, dry place.
Protection Keep in the original packaging to protect from light and moisture.
Security Store securely, out of the sight and reach of children and inaccessible to others.
Stability Do not use the tablets after the expiry date (EXP) printed on the package.

Disposal Instructions

Unused or expired medication should be disposed of promptly. Medicine take-back programs or DEA-registered collectors are the preferred disposal method. If these are unavailable, uncrushed tablets may be mixed with an unpalatable substance (like dirt or cat litter), sealed in a container, and thrown into the household trash. The tablets must not be disposed of into wastewater or flushed down a toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Panadeine (Acetaminophen,Codeine) found in:

A-Z Index: